DURYSTA®
(bimatoprost intracameral implant) 10 mcg

Procedure Consent Form

Approved Uses: DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

Patient Instructions: DURYSTA® is administered by your ophthalmologist. You should remain upright (do not recline or lie down) for at least 1 hour following the procedure to allow the implant to settle properly. If your eye becomes progressively red, sensitive to light, painful, or develops a change in vision, immediately call your doctor.

IMPORTANT SAFETY INFORMATION

DURYSTA® should not be used if:

- You have any infection or suspected infection in your eye or surrounding eye area
- You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems
- You have had a corneal transplant or cells transplanted to the inner layer of the cornea (endothelial cell transplant)
- The sack that surrounds the lens of your eye (posterior lens capsule) is missing or torn
- You are allergic to any of its ingredients

DURYSTA® may cause side effects involving the cornea, including increased risk of loss of cells from the inner layer of the cornea. You should not receive DURYSTA® more than once in each eye. DURYSTA® should be used with caution if you have a limited reserve of the cells lining the inner layer of the cornea.

DURYSTA® should be used with caution if you have narrow or obstructed iridocorneal angles (the space where the iris, the colored part of the eye, and cornea meet).

DURYSTA® may cause swelling of the macula, the center spot of the retina (back of the eye). DURYSTA® should be used with caution if your eye does not have a lens, if you have an artificial lens and a torn posterior lens capsule, or if you have any risk factors for swelling of the macula.

DURYSTA® may cause inflammation inside the eye or make existing inflammation worse.

DURYSTA® may cause increased brown coloring of the iris, which may be permanent.

Eye injections have been associated with infections in the eye. It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye redness, sensitivity to light, eye pain, or a change in vision, after an injection. Your doctor should monitor you following DURYSTA® administration.

The most common side effect involving the eyes reported in patients using DURYSTA® was eye redness. Other common side effects reported were: feeling like something is in your eye, eye pain, being sensitive to light, a blood spot on the white of your eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.

Please see accompanying full Prescribing Information or visit https://www.rxabbvie.com/pdf/durysta_pi.pdf

Consent: By signing, I acknowledge that I have read and fully understand this document and give my consent voluntarily to have the DURYSTA® procedure performed. I also acknowledge that if I have any questions, I have had the opportunity to have them answered by the physician/healthcare provider.

Patient/authorized person signature	Print name	Date

Allergan
an AbbVie company

US-DUR-220055 03/2022 015823